Special Issue "Cancer Molecular Biology and Drug Discovery"

A special issue of BioChem (ISSN 2673-6411).

Deadline for manuscript submissions: 31 January 2023 | Viewed by 25

Special Issue Editor

Dr. Pei-Ming Yang
E-Mail Website
Guest Editor
Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan
Interests: cancer biology; bioinformatics; drug repurposing
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cancer is a major health issue worldwide, with an increasing global burden in the coming years. Some malignancies, such as colorectal, breast, prostate, and pancreatic cancers, are still incurable in advanced stages. Thus, more effective anticancer drugs are always urgently needed. The process of drug discovery is still risky, lengthy, and costly, and only a few new anticancer drugs have received approval in recent years. Drug repurposing is an unconventional drug discovery approach to explore new disease indications from existing clinical drugs. Even shelved drugs that never enter or fail during clinical trials might be rescued if novel mechanisms of action (MOAs) or targets are identified. Polypharmacology describes the ability of a drug to affect more than one molecular target, which is now commonly accepted as a basic property of small molecules and serves as a foundational principle for drug repurposing. Exploring polypharmacology is highly useful for discovering drugs’ novel MOAs to improve their therapeutic efficacies and treat different diseases. The advantages of drug repurposing include a reduction in cost and the bypass of safety concerns because extensive drug data are often available.

This Special Issue will focus on the development of novel cancer therapy based on polypharmacology and drug repurposing strategies. We welcome original research articles and review articles in this field.

Dr. Pei-Ming Yang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. BioChem is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • cancer therapy
  • cancer biology
  • drug discovery
  • drug repurposing
  • polypharmacology

Published Papers

This special issue is now open for submission.
Back to TopTop